FDA Approves Acalabrutinib-Based Regimen for Previously Treated MCL

Summary by onclive.com

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated1 day agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

FDA Approves Acalabrutinib-Based Regimen for Previously Treated MCL

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics